[go: up one dir, main page]

RU2021107053A - Получение антигенспецифических t-клеток - Google Patents

Получение антигенспецифических t-клеток Download PDF

Info

Publication number
RU2021107053A
RU2021107053A RU2021107053A RU2021107053A RU2021107053A RU 2021107053 A RU2021107053 A RU 2021107053A RU 2021107053 A RU2021107053 A RU 2021107053A RU 2021107053 A RU2021107053 A RU 2021107053A RU 2021107053 A RU2021107053 A RU 2021107053A
Authority
RU
Russia
Prior art keywords
cells
expansion
population
enrichment
interest
Prior art date
Application number
RU2021107053A
Other languages
English (en)
Inventor
Матиас ЭЛЬКЕ
Хосе Луис САНТОС
Содзунг КИМ
Джонатан ШНЕК
Алисса КОСМИДЕС
Original Assignee
Нексиммьюн, Инк.
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нексиммьюн, Инк., Дзе Джонс Хопкинс Юниверсити filed Critical Нексиммьюн, Инк.
Publication of RU2021107053A publication Critical patent/RU2021107053A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)

Claims (15)

1. Способ скрининга популяции T-клеток на предмет реактивности по отношению к библиотеке антигенных пептидов, включающий:
магнитное обогащение и экспансирование антигенспецифических T-клеток в популяции при помощи коктейля парамагнитных частиц, каждая из которых имеет конъюгированный на поверхности антигенпрезентирующий комплекс ГКГС-пептид, который презентирует антигенный пептид, представляющий интерес,
и фенотипическую оценку экспансированных T-клеток.
2. Способ по п.1, в котором T-клетки и указанные парамагнитные наночастицы инкубируют в присутствии магнитного поля в течение по меньшей мере 5 минут.
3. Способ по п.2, в котором популяция T-клеток происходит из костного мозга, ткани лимфатического узла, ткани селезенки или опухоли.
4. Способ по п.3, в котором популяцию T-клеток выделяют при помощи лейкафереза.
5. Способ по любому из пп.1-4, в котором популяцию T-клеток обогащают CD8+ клетками или CD4+ клетками.
6. Способ по любому из пп.1-5, в котором популяция T-клеток содержит по меньшей мере 106 CD8+ клеток, CD4+ клеток.
7. Способ по любому из пп.1-6, в котором магнитно обогащенные клетки экспансируют в культуре в течение приблизительно 2 дней.
8. Способ по любому из пп. 1-7, в котором экспансированные T-клетки оценивают на предмет экспрессии цитокинов.
9. Способ по любому из пп.1-8, в котором последовательное обогащение и экспансию выполняют с применением проточной фракции (flow-through fraction), при этом в каждом последовательном обогащении и экспансии тестируют другой антигенный пептид, представляющий интерес.
10. Способ по п.9, в котором выполняют по меньшей мере шесть стадий последовательного обогащения и экспансии, и, необязательно, по меньшей мере десять стадий последовательного обогащения и экспансии.
11. Способ по п.10, в котором каждая стадия последовательного обогащения и экспансии включает от пяти до приблизительно 20 антигенных пептидов, представляющих интерес.
12. Способ по п.10 или п.11, в котором тестируют по меньшей мере 75 антигенов, или, необязательно, в котором тестируют по меньшей мере 100 антигенов.
13. Способ по любому из пп.1-12, в котором популяция T-клеток происходит от пациента, больного раком, пациента, имеющего аутоиммунное нарушение, или пациента, имеющего инфекционное заболевание.
RU2021107053A 2016-03-16 2017-03-16 Получение антигенспецифических t-клеток RU2021107053A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309234P 2016-03-16 2016-03-16
US62/309,234 2016-03-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018136203A Division RU2745319C2 (ru) 2016-03-16 2017-03-16 Получение антигенспецифических t-клеток

Publications (1)

Publication Number Publication Date
RU2021107053A true RU2021107053A (ru) 2021-08-24

Family

ID=59850933

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2021107053A RU2021107053A (ru) 2016-03-16 2017-03-16 Получение антигенспецифических t-клеток
RU2018136203A RU2745319C2 (ru) 2016-03-16 2017-03-16 Получение антигенспецифических t-клеток

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018136203A RU2745319C2 (ru) 2016-03-16 2017-03-16 Получение антигенспецифических t-клеток

Country Status (11)

Country Link
US (2) US20200291381A1 (ru)
EP (1) EP3445399A4 (ru)
JP (1) JP7016098B2 (ru)
KR (1) KR102470979B1 (ru)
CN (1) CN109475620A (ru)
AU (1) AU2017233035B2 (ru)
CA (1) CA3017615A1 (ru)
IL (1) IL261710A (ru)
RU (2) RU2021107053A (ru)
SG (2) SG11201807940XA (ru)
WO (1) WO2017161092A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
RU2020113627A (ru) * 2017-09-20 2021-10-20 Нексиммьюн, Инк. Композиции клеток, содержащие антигенспецифические т-клетки, для адоптивной терапии
US11598780B2 (en) 2017-10-06 2023-03-07 The University Of Chicago Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor
JP7580754B2 (ja) * 2018-06-20 2024-11-12 ダンマークス テクニスク ユニバーシテット 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド
IL281413B2 (en) * 2018-09-19 2024-09-01 Fujifilm Cellular Dynamics Inc Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
CN109136276A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种rfft2细胞的构建方法
CA3118757A1 (en) 2018-11-08 2020-05-14 Neximmune, Inc. T cell compositions with improved phenotypic properties
US20230104519A1 (en) * 2020-02-27 2023-04-06 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Cobra1/nelf-b as a booster for efficacy of cd8+ t cell-based therapy
EP4172352A4 (en) * 2020-06-26 2024-07-03 The Johns Hopkins University Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells
KR20230118166A (ko) * 2020-12-11 2023-08-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료를 위한 방법 및 물질
WO2023060217A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers
WO2023144275A1 (en) * 2022-01-28 2023-08-03 Katholieke Universiteit Leuven Actuation of organoids by magnetic nanoparticles
DE102022132082B4 (de) * 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2311920C2 (ru) * 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20120128656A1 (en) * 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
CN102168066A (zh) * 2011-01-31 2011-08-31 浙江大学 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法
WO2014011996A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
CA2906514C (en) * 2013-03-14 2021-07-27 Jonathan Schneck Nanoscale artificial antigen presenting cells
US11807675B2 (en) * 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
US10066265B2 (en) * 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포

Also Published As

Publication number Publication date
EP3445399A1 (en) 2019-02-27
AU2017233035B2 (en) 2021-08-05
KR20190026645A (ko) 2019-03-13
RU2745319C2 (ru) 2021-03-23
CN109475620A (zh) 2019-03-15
RU2018136203A3 (ru) 2020-06-22
US20200291381A1 (en) 2020-09-17
CA3017615A1 (en) 2017-09-21
SG11201807940XA (en) 2018-10-30
JP7016098B2 (ja) 2022-02-21
US20230332131A1 (en) 2023-10-19
AU2017233035A1 (en) 2018-11-01
IL261710A (en) 2018-10-31
EP3445399A4 (en) 2019-10-30
KR102470979B1 (ko) 2022-11-24
SG10202008210XA (en) 2020-10-29
WO2017161092A1 (en) 2017-09-21
JP2019513412A (ja) 2019-05-30
RU2018136203A (ru) 2020-04-16

Similar Documents

Publication Publication Date Title
RU2021107053A (ru) Получение антигенспецифических t-клеток
Dobrovolskienė et al. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines
JP2019519246A (ja) 免疫療法向けのｔ細胞組成物
AR107278A1 (es) Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos
EP3642331B1 (en) T-cell expansion method and uses
DE11787873T1 (de) Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
De Keersmaecker et al. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
AU2007347364A1 (en) Method for obtaining TREG-cells
IL273452B2 (en) Cell preparations comprising antigen-specific T cells for adoptive therapy
Kim et al. Use of engineered exosomes expressing HLA and costimulatory molecules to generate antigen-specific CD8+ T cells for adoptive cell therapy
Brimnes et al. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion
JP5840857B2 (ja) 細胞傷害性ｔ細胞誘導用組成物
Brabants et al. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA–loaded dendritic cells for cancer vaccination
TWI774957B (zh) 經調節之免疫優勢治療
RU2014148172A (ru) Способы индукции антигенспецифических регуляторных т-клеток
ten Brinke et al. Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential
Yee Adoptive therapy using antigen-specific T-cell clones
CN102746381A (zh) 一种幽门螺杆菌抗原hla限制性免疫显性表位肽及其制备方法和应用
ES2954480T3 (es) Métodos y materiales para expandir linfocitos T específicos de antígeno en cultivo
CN105481947A (zh) 结核分枝杆菌特异性cd4+t细胞表位肽p12及其应用
Karlsson et al. Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis
Tsuda et al. A human B cell receptor epitope-based erbB-2 peptide (N: 163-182) with pan-reactivity to the t cells of japanese breast cancer patients
Delluc et al. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method
WO2022253957A1 (en) Person-tailored t cell composition targeting merkel cell carcinoma
Liu et al. Soluble CD40 ligand-activated B cells from patients with chronic hepatitis B virus infection as antigen presenting cells to induce hepatitis B virus specific cytotoxic T lymphocytes